Glioma is a broad category of brain and spinal cord tumors that comes from glial cells. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors considered to be among the deadliest of human cancers. In its most aggressive manifestation, glioblastoma (GBM), median survival ranges from 9 to 12 months. The overall annual incidence of gliomas is in the range of 5–6/100,000.
Current treatment options include surgery, radiation, and chemotherapy. Surgery combined with radiotherapy and chemotherapy has proven to prolong patient survival. However, patients diagnosed with malignant glioma who are treated with traditional therapeutic methods often experience harmful side effects like loss of cognitive process from surgery, inflammatory responses from chemotherapy or even induction of secondary cancers from radiation therapy. No one of current methods is able to completely cure the disease.
There are several novel approaches to treatment of glioma:
Most of novel methods use molecular biomarkers of glioma. But there is lack in biomarkers' databases. This database accumulates receptor biomarkers of glioma.